# Outcome of Use of a Novel Modulator of Oxidative Phosphorylation on Kidney Function in Patients With Progressive Chronic Kidney Disease

> **NCT07150338** · — · COMPLETED · sponsor: **Neukidney Inc.** · enrollment: 45 (actual)

## Conditions studied

- Chronic Kidney Disease (Stage 3-4)
- Chronic Kidney Disease (Stages 4 and 5)
- Proteinuria

## Interventions

- **DRUG:** QRX-3
- **DRUG:** Eseronate

## Key facts

- **NCT ID:** NCT07150338
- **Lead sponsor:** Neukidney Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-20
- **Primary completion:** 2022-04-20
- **Final completion:** 2022-11-20
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07150338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07150338, "Outcome of Use of a Novel Modulator of Oxidative Phosphorylation on Kidney Function in Patients With Progressive Chronic Kidney Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07150338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*